-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Revance Therapeutics Analyst Ratings
Revance Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/22/2022 | 27.91% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
09/09/2022 | 16.28% | Mizuho | $26 → $30 | Maintains | Buy |
09/09/2022 | 35.66% | Barclays | $22 → $35 | Maintains | Overweight |
09/09/2022 | 12.4% | HC Wainwright & Co. | $25 → $29 | Maintains | Buy |
09/09/2022 | 35.66% | Needham | $25 → $35 | Maintains | Buy |
08/25/2022 | -6.98% | Wells Fargo | $17 → $24 | Maintains | Equal-Weight |
10/26/2021 | -14.73% | Barclays | $33 → $22 | Maintains | Overweight |
10/25/2021 | -34.11% | Wells Fargo | → $17 | Downgrades | Overweight → Equal-Weight |
10/18/2021 | -3.1% | Needham | $45 → $25 | Maintains | Buy |
10/18/2021 | -30.23% | HC Wainwright & Co. | $26 → $18 | Maintains | Buy |
10/13/2021 | 0.78% | HC Wainwright & Co. | $35 → $26 | Maintains | Buy |
08/06/2021 | 27.91% | Barclays | $32 → $33 | Maintains | Overweight |
02/23/2021 | 35.66% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
01/08/2021 | 74.42% | Needham | $42 → $45 | Maintains | Buy |
10/15/2020 | 62.79% | Needham | $36 → $42 | Maintains | Buy |
04/16/2020 | 20.16% | Stifel | $35 → $31 | Maintains | Buy |
04/01/2020 | 35.66% | Mizuho | $39 → $35 | Maintains | Buy |
03/27/2020 | -6.98% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
03/23/2020 | -41.86% | Goldman Sachs | $32 → $15 | Downgrades | Buy → Neutral |
02/25/2020 | 55.04% | Piper Sandler | $37 → $40 | Reiterates | → Overweight |
02/25/2020 | 39.53% | Needham | $32 → $36 | Maintains | Buy |
02/18/2020 | 43.41% | Piper Sandler | $38 → $37 | Maintains | Overweight |
01/23/2020 | 51.16% | Mizuho | $34 → $39 | Maintains | Buy |
12/02/2019 | -3.1% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
10/30/2019 | -22.48% | Wells Fargo | $12.5 → $20 | Upgrades | Market Perform → Outperform |
06/11/2019 | 8.53% | Barclays | → $28 | Initiates Coverage On | → Overweight |
02/15/2019 | — | Wells Fargo | Initiates Coverage On | → Market Perform | |
02/14/2019 | -3.1% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
01/29/2019 | 93.8% | Stifel | → $50 | Initiates Coverage On | → Buy |
11/16/2018 | 58.91% | Guggenheim | → $41 | Upgrades | Neutral → Buy |
09/17/2018 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
03/05/2018 | 132.56% | Goldman Sachs | → $60 | Initiates Coverage On | → Buy |
01/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
12/06/2017 | 62.79% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
11/27/2017 | 20.16% | Barclays | → $31 | Initiates Coverage On | → Overweight |
11/17/2017 | 43.41% | Mizuho | → $37 | Initiates Coverage On | → Buy |
Revance Therapeutics Questions & Answers
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on September 22, 2022. The analyst firm set a price target for $33.00 expecting RVNC to rise to within 12 months (a possible 27.91% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Goldman Sachs, and Revance Therapeutics initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on September 22, 2022 so you should expect the next rating to be made available sometime around September 22, 2023.
While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a initiated with a price target of $0.00 to $33.00. The current price Revance Therapeutics (RVNC) is trading at is $25.80, which is within the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/22/2022 | 27.91% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
09/09/2022 | 16.28% | Mizuho | $26 → $30 | Maintains | Buy |
09/09/2022 | 35.66% | Barclays | $22 → $35 | Maintains | Overweight |
09/09/2022 | 12.4% | HC Wainwright & Co. | $25 → $29 | Maintains | Buy |
09/09/2022 | 35.66% | Needham | $25 → $35 | Maintains | Buy |
08/25/2022 | -6.98% | Wells Fargo | $17 → $24 | Maintains | Equal-Weight |
10/26/2021 | -14.73% | Barclays | $33 → $22 | Maintains | Overweight |
10/25/2021 | -34.11% | Wells Fargo | → $17 | Downgrades | Overweight → Equal-Weight |
10/18/2021 | -3.1% | Needham | $45 → $25 | Maintains | Buy |
10/18/2021 | -30.23% | HC Wainwright & Co. | $26 → $18 | Maintains | Buy |
10/13/2021 | 0.78% | HC Wainwright & Co. | $35 → $26 | Maintains | Buy |
08/06/2021 | 27.91% | Barclays | $32 → $33 | Maintains | Overweight |
02/23/2021 | 35.66% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
01/08/2021 | 74.42% | Needham | $42 → $45 | Maintains | Buy |
10/15/2020 | 62.79% | Needham | $36 → $42 | Maintains | Buy |
04/16/2020 | 20.16% | Stifel | $35 → $31 | Maintains | Buy |
04/01/2020 | 35.66% | Mizuho | $39 → $35 | Maintains | Buy |
03/27/2020 | -6.98% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
03/23/2020 | -41.86% | Goldman Sachs | $32 → $15 | Downgrades | Buy → Neutral |
02/25/2020 | 55.04% | Piper Sandler | $37 → $40 | Reiterates | → Overweight |
02/25/2020 | 39.53% | Needham | $32 → $36 | Maintains | Buy |
02/18/2020 | 43.41% | Piper Sandler | $38 → $37 | Maintains | Overweight |
01/23/2020 | 51.16% | Mizuho | $34 → $39 | Maintains | Buy |
12/02/2019 | -3.1% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
10/30/2019 | -22.48% | Wells Fargo | $12.5 → $20 | Upgrades | Market Perform → Outperform |
06/11/2019 | 8.53% | Barclays | → $28 | Initiates Coverage On | → Overweight |
02/15/2019 | — | Wells Fargo | Initiates Coverage On | → Market Perform | |
02/14/2019 | -3.1% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
01/29/2019 | 93.8% | Stifel | → $50 | Initiates Coverage On | → Buy |
11/16/2018 | 58.91% | Guggenheim | → $41 | Upgrades | Neutral → Buy |
09/17/2018 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
03/05/2018 | 132.56% | Goldman Sachs | → $60 | Initiates Coverage On | → Buy |
01/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
12/06/2017 | 62.79% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
11/27/2017 | 20.16% | Barclays | → $31 | Initiates Coverage On | → Overweight |
11/17/2017 | 43.41% | Mizuho | → $37 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
09/22/2022 | 27.91% | 高盛 | → 33 美元 | 启动覆盖范围开启 | → 购买 |
09/09/2022 | 16.28% | 瑞穗市 | 26 美元 → 30 美元 | 维持 | 购买 |
09/09/2022 | 35.66% | 巴克莱 | 22 美元 → 35 美元 | 维持 | 超重 |
09/09/2022 | 12.4% | HC Wainwright & Co. | 25 美元 → 29 美元 | 维持 | 购买 |
09/09/2022 | 35.66% | 尼德姆 | 25 美元 → 35 美元 | 维持 | 购买 |
08/25/2022 | -6.98% | 富国银行 | 17 美元 → 24 美元 | 维持 | 等重 |
10/26/2021 | -14.73% | 巴克莱 | 33 美元 → 22 美元 | 维持 | 超重 |
2021 年 10 月 25 日 | -34.11% | 富国银行 | → 17 美元 | 降级 | 超重 → 重量相等 |
2021 年 10 月 18 日 | -3.1% | 尼德姆 | 45 美元 → 25 美元 | 维持 | 购买 |
2021 年 10 月 18 日 | -30.23% | HC Wainwright & Co. | 26 美元 → 18 美元 | 维持 | 购买 |
10/13/2021 | 0.78% | HC Wainwright & Co. | 35 美元 → 26 美元 | 维持 | 购买 |
08/06/2021 | 27.91% | 巴克莱 | 32 美元 → 33 美元 | 维持 | 超重 |
2021 年 2 月 23 日 | 35.66% | HC Wainwright & Co. | 33 美元 → 35 美元 | 维持 | 购买 |
01/08/2021 | 74.42% | 尼德姆 | 42 美元 → 45 美元 | 维持 | 购买 |
2020 年 10 月 15 日 | 62.79% | 尼德姆 | 36 美元 → 42 美元 | 维持 | 购买 |
2020 年 4 月 16 日 | 20.16% | Stifel | 35 美元 → 31 美元 | 维持 | 购买 |
2020 年 1 月 4 日 | 35.66% | 瑞穗市 | 39 美元 → 35 美元 | 维持 | 购买 |
03/27/2020 | -6.98% | HC Wainwright & Co. | 28 美元 → 24 美元 | 重申 | → 购买 |
03/23/2020 | -41.86% | 高盛 | 32 美元 → 15 美元 | 降级 | 买入 → 中性 |
2020 年 2 月 25 日 | 55.04% | 派珀·桑德勒 | 37 美元 → 40 美元 | 重申 | → 超重 |
2020 年 2 月 25 日 | 39.53% | 尼德姆 | 32 美元 → 36 美元 | 维持 | 购买 |
02/18/2020 | 43.41% | 派珀·桑德勒 | 38 美元 → 37 美元 | 维持 | 超重 |
01/23/2020 | 51.16% | 瑞穗市 | 34 美元 → 39 美元 | 维持 | 购买 |
12/02/2019 | -3.1% | 高盛 | → 25 美元 | 启动覆盖范围开启 | → 购买 |
10/30/2019 | -22.48% | 富国银行 | 12.5 美元 → 20 美元 | 升级 | 市场表现 → 跑赢大盘 |
2019 年 11 月 6 日 | 8.53% | 巴克莱 | → 28 美元 | 启动覆盖范围开启 | → 超重 |
02/15/2019 | — | 富国银行 | 启动覆盖范围开启 | → 市场表现 | |
02/14/2019 | -3.1% | HC Wainwright & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 1 月 29 日 | 93.8% | Stifel | → 50 美元 | 启动覆盖范围开启 | → 购买 |
11/16/2018 | 58.91% | 古根海姆 | → 41 美元 | 升级 | 中性 → 买入 |
09/17/2018 | — | JMP 证券 | 降级 | 市场跑赢大盘 → 市场表现 | |
03/05/2018 | 132.56% | 高盛 | → 60 美元 | 启动覆盖范围开启 | → 购买 |
01/09/2018 | — | 古根海姆 | 降级 | 买入 → 中性 | |
2017 年 6 月 12 日 | 62.79% | 古根海姆 | → 42 美元 | 启动覆盖范围开启 | → 购买 |
11/27/2017 | 20.16% | 巴克莱 | → 31 美元 | 启动覆盖范围开启 | → 超重 |
11/17/2017 | 43.41% | 瑞穗市 | → 37 美元 | 启动覆盖范围开启 | → 购买 |
Revance Therapeutics Questions & Answers
Revance 疗法问题与解答
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on September 22, 2022. The analyst firm set a price target for $33.00 expecting RVNC to rise to within 12 months (a possible 27.91% upside). 11 analyst firms have reported ratings in the last year.
高盛于2022年9月22日公布了Revance Therapeutics(纳斯达克股票代码:RVNC)的最新目标股价。该分析公司将目标股价定为33.00美元,预计RVNC将在12个月内上涨至33.00美元(可能上涨27.91%)。去年有11家分析公司公布了评级。
The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Goldman Sachs, and Revance Therapeutics initiated their buy rating.
Revance Therapeutics(纳斯达克股票代码:RVNC)的最新分析师评级由高盛提供,Revance Therapeutics启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on September 22, 2022 so you should expect the next rating to be made available sometime around September 22, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Revance Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Revance Therapeutics的最后一次评级是在2022年9月22日公布的,因此您应该预计下一个评级将在2023年9月22日左右公布。
While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a initiated with a price target of $0.00 to $33.00. The current price Revance Therapeutics (RVNC) is trading at is $25.80, which is within the analyst's predicted range.
尽管评级是主观的,并将发生变化,但最新的Revance Therapeutics(RVNC)评级是启动的,目标股价为0.00美元至33.00美元。Revance Therapeutics(RVNC)目前的交易价格为25.80美元,在分析师的预测区间内。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧